Background. The article presents data on somatic mutations found in the Russian population of patients with non-small cell lung cancer (NSCLC), their frequency, distribution depending on the histological type of tumor.Aim. To study the molecular genetic profile of Russian patients with stage I–IIIA localized NSCLC, the frequency of occurrence of various somatic mutations, variants of the switching status.Materials and methods. Genetic testing for a panel of 78 genes using the Next Generation Sequencing method of tumor material obtained after surgical treatment of 65 patients with localized stage I–IIIA NSCLC. Processing of the received data was carried out by methods of descriptive statistics.43Results. Mutations in the EGFR, ALK, ROS1, RET, BRAF, KRAS, MET, HER2 genes were found only in adenocarcinoma. Among non-targeted mutations in adenocarcinoma, TP53, STK11, FGFR3, EML4, NF1, RB1, and KMTC2 mutations were the most common. In squamous cell lung cancer, TP53, KMT2C, TSC1, EML4, PTEN, NF1, COL22A1, CDKN2A, RB1, BRCA1 were the most common. Mutations in the EGFR gene were most often associated with mutations in TP53 (30 % of cases), RB1 (15 % of cases), COL22A1 (15 % of cases); ALK was combined with TP53, NF1, WT1 – in 33 % of cases, ROS1 with DDR2 (33 % of cases), ERBB2 was combined with NTRK1, GPC3, HIP1, KIF5B, TP53, XPC, COL22A1 – in 14 % of cases, BRAF was most often associated with mutations in the TP53 gene (14 %) and COL22A1 (13.8 %); a mutation in the RET gene was associated with a TP53 mutation; ROS1 translocation in 50 % of cases was associated with mutations in the TRIM33 and TP53 genes.Conclusion. The data obtained give an idea of the frequency of occurrence of somatic mutations among Russian patients with NSCLC, which is important for the selection of diagnostic panels, interpretation of their results, and also potentially for the development of original custom Next Generation Sequencing testing panels.
Read full abstract